SCHEMBL268204

SCHEMBL268204

NCC(Cl)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluoride SCHEMBL11070678 0.95
Hydrochloric Acid SCHEMBL931074 0.95
Hydrochloric Acid SCHEMBL28650740 0.95 ALDH1A1 (0.33)
SCHEMBL9998985 0.74
SCHEMBL856466 0.74
SCHEMBL10836077 0.70 ALDH1A1 (0.40)
SCHEMBL11235424 0.70
SCHEMBL8726333 0.70 ALDH1A1 (0.40)
SCHEMBL1160713 0.70
Hydrochloric Acid SCHEMBL9998722 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108508-A1 TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2026-04-23 US claimed
EP-4486924-A2 NUCLEIC ACID CROSSLINKING REAGENTS AND USES THEREOF Promega Corporation (US) 2025-01-08 EP claimed
US-20240139179-A1 TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2024-05-02 US claimed
CN-115536610-B Preparation method of vothixetine 湖南省湘中制药有限公司 2024-01-23 CN claimed
US-20230366045-A1 NUCLEIC ACID CROSSLINKING REAGENTS AND USES THEREOF PROMEGA CORPORATION 2023-11-16 US claimed
CN-116829154-A Compounds for the prevention, treatment and diagnosis of thrombosis 国家健康科学研究所 2023-09-29 CN claimed
WO-2023177976-A2 NUCLEIC ACID CROSSLINKING REAGENTS AND USES THEREOF PROMEGA CORPORATION (US) 2023-09-21 WO claimed
CN-116601307-A Nucleic acid modification reagent and use thereof 普罗美加公司 2023-08-15 CN claimed
US-20230241057-A1 COMPOUNDS FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF THROMBI UNIVERSITE PARIS 13 PARIS-NORD (FR) 2023-08-03 US claimed
EP-4208564-A1 NUCLEIC ACID MODIFYING REAGENTS AND USES THEREOF Promega Corporation (US) 2023-07-12 EP claimed
EP-1383379-A1 RESTORATION OF CANCER-SUPPRESSING FUNCTIONS TO NEOPLASTIC CELLS THROUGH DNA HYPOMETHYLATION SuperGen, Inc. (US) 2004-01-28 EP claimed
US-20030191179-A1 Methods for administration of paclitaxel SUPERGEN, INC. 2003-10-09 US claimed
EP-1276479-A2 INHIBITION OF ABNORMAL CELL PROLIFERATION WITH CAMPTOTHECIN AND COMBINATIONS INCLUDING THE SAME SuperGen, Inc. (US) 2003-01-22 EP claimed
WO-2002085400-A1 COMPOSITIONS AND METHODS FOR REESTABLISHING GENE TRANSCRIPTION THROUGH INHIBITION OF DNA METHYLATION AND HISTONE DEACETYLASE SUPERGEN, INC. (US) 2002-10-31 WO claimed
WO-2002067681-A1 RESTORE CANCER-SUPPRESSING FUNCTIONS TO NEOPLASTIC CELLS THROUGH DNA HYPOMETHYLATION SUPERGEN, INC. (US) 2002-09-06 WO claimed
US-20020114809-A1 Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation ASTEX PHARMACEUTICALS, INC. 2002-08-22 US claimed
US-20020111362-A1 Inhibition of abnormal cell proliferation with camptothecin and combinations including the same SUPERGEN, INC. 2002-08-15 US claimed
WO-2001080843-A2 INHIBITION OF ABNORMAL CELL PROLIFERATION WITH CAMPTOTHECIN AND COMBINATIONS INCLUDING THE SAME SUPERGEN, INC. (US) 2001-11-01 WO claimed
CN-1066444-C Nitrogenous derivs. of elemene and their use as anticancer drugs DALIAN CHEMICAL PHYSICS INST (CN) 2001-05-30 CN claimed
CN-1153167-A Nitrogenous derivs. of elemene and their use as anticancer drugs DALIAN CHEMICAL PHYSICS INST (CN) 1997-07-02 CN claimed